Previous 10 | Next 10 |
home / stock / azncf / azncf news
Summary Japan just approved three drugs against cancer and leukemia. AstraZeneca increased its 2022 guidance. As already mentioned, premium pipelines deserve a premium valuation. The company is confirming a positive trajectory both in its internal R&D area as well as inorganical...
Summary We share data on over 50 big-yield healthcare investments, including individual stocks, REITs, closed-end funds ("CEFs") and bonds. We dive deeper into three specific attractive big-yield opportunities that also have healthy upside potential. We begin with a special focus on...
Summary Almost 60 percent of VEU’s AUM is invested in four sectors - ICT, financial, industrial, and healthcare. The fund generates decent yield and total returns. The strong US dollar, high sustained interest rate by the Fed, and slowing global economic growth are expected to we...
Summary On Monday, Madrigal Pharmaceuticals announced a best-case dataset from its phase 3 trial in NASH. This opens up a Huge market for the company. Madrigal Pharmaceuticals stock is up 4x: what you should do now. I have been bullish on Madrigal ( MDGL ) since 20...
Summary Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high, longer than expected. The pandemic vaccine/antiviral income windfall has moved its balance sheet into a super-conservative and liquid setting. Valua...
Summary The IOO ETF is mostly just a value weighted US portfolio, with European exposures consisting primarily of healthcare and consumer staple exposures. We think geopolitics is the most important factor, and the US is in a great position eating Europe's lunch. America continues t...
Summary Shares of early clinical-stage biotech Tango Therapeutics, Inc. are down ~50% since going public in August 2021 – primarily victimized by a lack of catalysts and a tough market. However, the shares have rallied strongly over the past month. Tango Therapeutics...
AstraZeneca PLC (AZN) Q3 2022 Earnings Conference Call November 10, 2022 06:45 AM ET Company Participants Andy Barnett - Head of Investor Relations Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO David Fredrickson - Exec...
The following slide deck was published by AstraZeneca PLC in conjunction with their 2022 Q3 earnings call. For further details see: AstraZeneca PLC 2022 Q3 - Results - Earnings Call Presentation
Summary Fisher’s 13F portfolio value decreased from ~$141B to ~$133B in Q3 2022. They added Charles Schwab and increased Nvidia, Morgan Stanley, and Goldman Sachs while decreasing Salesforce, Visa, Alibaba Group Holdings, Novartis, Verizon, and Tencent Holdings. The top...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...